Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

- 1-61. (Cancelled)
- 62. (Currently amended) A method for treating Tumor Necrosis Factor-alpha (TNF α) mediated immune reaction that causes corneal transplant rejection in a patient, comprising topically administering <u>directly</u> to <u>the eye of</u> said patient an effective amount of anti-TNF α F(ab')₂ neutralizing antibody fragments.
- 63. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are polyclonal.
- 64. (Previously presented) The method of claim 63, wherein said anti-TNFα F(ab')₂ neutralizing antibody fragments are free of albumin, whole antibodies, pyrogens, and/or viruses.
- 65. (Currently amended) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in combination with a dermatologically or ophatalmically opthalmically acceptable carrier.
- 66. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered within 24 hours following a corneal transplant in said patient.
- 67. (New) The method of claim 66, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered within 2 hours following a corneal transplant in said patient.

- 68. (New) The method of claim 67, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered within 30 minutes following a corneal transplant in said patient.
- 69. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered at least 3 times a day for about 8 weeks.
- 70. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered about every 10 to 12 hours for about 8 weeks.
- 71. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in an ophthalmic suspension or ointment.
- 72. (New) The method of claim 71, wherein said ophthalmic suspension or ointment comprises about 20 mg/ml to about 30 mg/ml of said anti-TNF α F(ab')₂ neutralizing antibody fragments.
- 73. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a composition comprising:
- (i) about 20 mg/ml to about 30 mg/ml of anti-TNF α F(ab')₂ neutralizing antibody fragments;
- (ii) about 0.01% to about 1% by weight of an anesthetic agent and dermatologically acceptable excipients;
 - (iii) about 1% to about 40% by weight urea; and
- (iv) about 0.01% to about 1% by weight of calcium acetate, ammonium sulfate, or a mixture thereof.
- 74. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a composition comprising:

- (i) about 20 mg/ml to about 30 mg/ml of anti-TNF α F(ab')₂ neutralizing antibody fragments; and
 - (ii) a penetration-enhancing system consisting essentially of:
 - (a) a membrane fluidizer comprising oleic acid;
 - (b) a C_1 - C_4 alcohol; and
 - (c) a glycol having a pH between 4 and 8.
- 75. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a composition comprising:
- (i) about 20 mg/ml to about 30 mg/ml of anti-TNF α F(ab')₂ neutralizing antibody fragments;
 - (ii) about 1% by weight laureth-4;
 - (iii) about 2% by weight propylene glycol;
 - (iv) about 0.5% by weight dimethylsorbide; and
- (v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
- 76. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a dermatologically acceptable gel vehicle comprising about 0.01% to about 50% by weight of anti-TNF α F(ab')₂ neutralizing antibody fragments.
- 77. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a dermatologically acceptable semi-solid vehicle comprising about 0.01% to about 50% by weight of anti-TNF α F(ab')₂ neutralizing antibody fragments.